Notice regarding head office relocation

On October 1, 2024, our company relocated its head office from Chuo-ku, Tokyo to Aoba-ku, Sendai City, Miyagi Prefecture, and a location announcement ceremony was officially held at Sendai City Hall on October 10, 2024. On that day, Chairman Miyata and President Furuta visited Sendai City Hall, submitted a location announcement to Sendai Mayor Kazuko Kohri and explained the purpose of the head office relocation. The new head office location (2-1 Seiryo-cho, Aoba-ku, Sendai City, Miyagi Prefecture) is located within the Tohoku University Seiryo Campus, where Tohoku University Hospital and the Tohoku University Graduate School of Medicine are located, so Professor Hideo Harigae, Vice President of Tohoku University (Medical and Co-Creation Strategy), was also in attendance.

Our company was listed in the Growth Market of the Tokyo Stock Exchange in September 2021. We believe that there is a need for a place where cutting-edge scientific and technological achievements can be utilized in many disease areas, a place for face-to-face interaction with doctors and researchers, and a place for open innovation with government and medical industry companies. Therefore, in January 2022, after going public, we opened our research lab, named TREx (Tohoku University x Renascience) within the campus of the Tohoku University Graduate School of Medicine. TREx is the first model based on the “Agreement on Regional Economic Development between Sendai City and Tohoku University” concluded in April 2021. It has been about two and a half years since it started operating, and during that time the development stage of research seeds has steadily increased, and new seeds are also increasing. The number of investigator-initiated clinical trials has also steadily increased, and currently about 10 cases are in operation per year.

Until now, our company’s headquarters were in Nihonbashi-Honcho, Tokyo, but since research and development-based bio-tech start-up companies like ours can take advantage of the geographical advantages of an area filled with universities and other research institutes and medical institutions, we have moved our research facilities and headquarters to the Tohoku University Seiryo Campus, where the Tohoku University Hospital and Graduate School of Medicine are located.

We have been able to significantly expand our research activities, such as accelerating investigator-initiated clinical trials through close collaboration with Tohoku University Hospital and developing and exploring seeds through collaboration with research institutions such as the Graduate School of Medicine. We have also been able to hire many employees, including researchers from the Tohoku University. Currently, we are conducting two Phase III investigator-initiated clinical trials for unapproved drugs (chronic myeloid leukemia and malignant melanoma), which is still rare even among domestic bio-tech start-up company. In addition, our drug for the treatment of malignant melanoma was designated as a orphan disease drug by the Ministry of Health, Labor and Welfare in August 2024. We think these are great achievements of establishing a research base in Sendai. With the relocation of our headquarters as an opportunity, we would like to further accelerate our research and business development.

Overview of Rena Science Co., Ltd.

Head office location: 202, Faculty of Medicine Building 6, 2-1 Seiryo-cho, Aoba-ku, Sendai, Miyagi Prefecture 980-8575

Telephone: 022-727-5070 (Main)

Representative: Keisuke Furuta, Representative Director and President

Stock formula: Tokyo Stock Exchange (stock code: 4889)

Founded: February 15, 2000

Capital: 1,036,808,000 yen

Number of employees: 15 (including executives, temporary employees, etc.)

Business details: Development and sales of pharmaceuticals, medical devices, programmed medical devices using artificial intelligence (AI), etc.

URL：https://www.renascience.co.jp/